Dual Trigger with Gonadotropin Releasing Hormone Agonist and Human Chorionic Gonadotropin of Fresh Autologous Cycles in High Responders: A Systematic Review.

Andreas A Vyrides, Essam El Mahdi, Demetris Lamnisos, Konstantinos Giannakou
{"title":"Dual Trigger with Gonadotropin Releasing Hormone Agonist and Human Chorionic Gonadotropin of Fresh Autologous Cycles in High Responders: A Systematic Review.","authors":"Andreas A Vyrides,&nbsp;Essam El Mahdi,&nbsp;Demetris Lamnisos,&nbsp;Konstantinos Giannakou","doi":"10.18502/jri.v23i1.8446","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The purpose of the current study was to investigate the effect of co-administration of human chorionic gonadotropin (hCG) with gonadotropin releasing hormone agonist (GnRH-a) trigger (dual trigger) in high responders for fresh autologous cycles in order to investigate the pregnancy outcomes and rates of ovarian hyperstimulation syndrome (OHSS) in comparison to GnRH-a trigger alone.</p><p><strong>Methods: </strong>A systematic search was performed in PubMed and Ovid MEDLINE from inception through February 2020. The included materials were case-control, cohort and, cross-sectional studies as well as clinical trials in which the outcomes of dual trigger with GnRH-a were compared for final oocyte maturation in high responders undergoing GnRH-ant cycles.</p><p><strong>Results: </strong>Five retrospective studies were included for this review. Three of the studies showed that the use of dual trigger versus GnRH-a trigger resulted in no statistically significant difference in rates of OHSS while achieving a statistically significant difference in favor of the dual trigger group in ongoing pregnancy rates, early pregnancy loss, and fertilization rates.</p><p><strong>Conclusion: </strong>Currently, there is insufficient evidence to support improved clinical pregnancy rate, fertilization rate, live birth rate, and early pregnancy loss rate by the use of dual trigger versus GnRH-a trigger. Larger double-blind clinical studies are required to properly evaluate the efficacy of this protocol for use in high responders.</p>","PeriodicalId":38826,"journal":{"name":"Journal of Reproduction and Infertility","volume":"23 1","pages":"3-17"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/d1/JRI-23-3.PMC9361727.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Reproduction and Infertility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jri.v23i1.8446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The purpose of the current study was to investigate the effect of co-administration of human chorionic gonadotropin (hCG) with gonadotropin releasing hormone agonist (GnRH-a) trigger (dual trigger) in high responders for fresh autologous cycles in order to investigate the pregnancy outcomes and rates of ovarian hyperstimulation syndrome (OHSS) in comparison to GnRH-a trigger alone.

Methods: A systematic search was performed in PubMed and Ovid MEDLINE from inception through February 2020. The included materials were case-control, cohort and, cross-sectional studies as well as clinical trials in which the outcomes of dual trigger with GnRH-a were compared for final oocyte maturation in high responders undergoing GnRH-ant cycles.

Results: Five retrospective studies were included for this review. Three of the studies showed that the use of dual trigger versus GnRH-a trigger resulted in no statistically significant difference in rates of OHSS while achieving a statistically significant difference in favor of the dual trigger group in ongoing pregnancy rates, early pregnancy loss, and fertilization rates.

Conclusion: Currently, there is insufficient evidence to support improved clinical pregnancy rate, fertilization rate, live birth rate, and early pregnancy loss rate by the use of dual trigger versus GnRH-a trigger. Larger double-blind clinical studies are required to properly evaluate the efficacy of this protocol for use in high responders.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
促性腺激素释放激素激动剂和人绒毛膜促性腺激素在新鲜自体周期高应答者中的双重触发:系统综述。
背景:本研究的目的是探讨人绒毛膜促性腺激素(hCG)与促性腺激素释放激素激动剂(GnRH-a)触发器(双触发器)共同给药对新鲜自体周期高反应者的影响,以研究妊娠结局和卵巢过度刺激综合征(OHSS)的发生率,与单独GnRH-a触发器相比。方法:系统检索PubMed和Ovid MEDLINE从成立到2020年2月。纳入的材料包括病例对照、队列和横断面研究以及临床试验,其中比较了GnRH-a双重触发对经历GnRH-ant周期的高反应者最终卵母细胞成熟的结果。结果:本综述纳入了5项回顾性研究。其中三项研究表明,使用双触发与GnRH-a触发在OHSS发生率上无统计学差异,而双触发组在持续妊娠率、早期妊娠丢失和受精率上有统计学显著差异。结论:目前尚没有足够的证据支持双触发与GnRH-a触发相比可提高临床妊娠率、受精率、活产率和早期妊娠损失率。需要更大规模的双盲临床研究来正确评估该方案用于高反应者的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Reproduction and Infertility
Journal of Reproduction and Infertility Medicine-Reproductive Medicine
CiteScore
2.70
自引率
0.00%
发文量
44
期刊最新文献
A Bizarre Case of Periovarian Hematoma in a Patient Undergoing Controlled Ovarian Stimulation Managed Conservatively. Abandoned Cryopreserved Embryos: The Unresolved Challenge. Comparative Analysis of the Effects of Magnesium Oxide Nanoparticles on Sperm Parameters in Fresh and Frozen Samples. Comparison of the Effect of Fenugreek and Metformin on Clinical and Metabolic Status of Cases with Polycystic Ovary Syndrome: A Randomized Trial. Evaluation of the Effect of Embryo Transfer Methods on Pregnancy Outcomes: A Retrospective Study and Future Perspectives.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1